These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 24281041)

  • 1. Telmisartan protects against vascular dysfunction with peroxisome proliferator-activated receptor-γ activation in hypertensive 5/6 nephrectomized rats.
    Toba H; Wang J; Ohigashi M; Kobara M; Nakata T
    Pharmacology; 2013; 92(5-6):265-75. PubMed ID: 24281041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor-γ in subtotal nephrectomized rat.
    Toba H; Tojo C; Wang J; Noda K; Kobara M; Nakata T
    Eur J Pharmacol; 2012 Jun; 685(1-3):91-8. PubMed ID: 22314223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice.
    Iwanami J; Mogi M; Tsukuda K; Min LJ; Sakata A; Jing F; Iwai M; Horiuchi M
    J Hypertens; 2010 Aug; 28(8):1730-7. PubMed ID: 20498620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats.
    Kobayashi N; Ohno T; Yoshida K; Fukushima H; Mamada Y; Nomura M; Hirata H; Machida Y; Shinoda M; Suzuki N; Matsuoka H
    Am J Hypertens; 2008 May; 21(5):576-81. PubMed ID: 18437150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia.
    Nagashima A; Watanabe R; Ogawa M; Suzuki J; Masumura M; Hishikari K; Shimizu T; Takayama K; Hirata Y; Nagai R; Isobe M
    J Cardiovasc Pharmacol; 2012 Aug; 60(2):158-64. PubMed ID: 22561360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
    Kusunoki H; Taniyama Y; Azuma J; Iekushi K; Sanada F; Otsu R; Iwabayashi M; Okayama K; Rakugi H; Morishita R
    Hypertension; 2012 Feb; 59(2):308-16. PubMed ID: 22252391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice.
    Min LJ; Mogi M; Shudou M; Jing F; Tsukuda K; Ohshima K; Iwanami J; Horiuchi M
    Hypertension; 2012 May; 59(5):1079-88. PubMed ID: 22454480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.
    Imayama I; Ichiki T; Inanaga K; Ohtsubo H; Fukuyama K; Ono H; Hashiguchi Y; Sunagawa K
    Cardiovasc Res; 2006 Oct; 72(1):184-90. PubMed ID: 16938288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activity.
    Toyama K; Nakamura T; Kataoka K; Yasuda O; Fukuda M; Tokutomi Y; Dong YF; Ogawa H; Kim-Mitsuyama S
    Biochem Biophys Res Commun; 2011 Jul; 410(3):508-13. PubMed ID: 21679694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change.
    Ikejima H; Imanishi T; Tsujioka H; Kuroi A; Kobayashi K; Shiomi M; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
    J Hypertens; 2008 May; 26(5):964-72. PubMed ID: 18398339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-gamma dependent pathway.
    Sugimoto K; Kazdová L; Qi NR; Hyakukoku M; Kren V; Simáková M; Zídek V; Kurtz TW; Pravenec M
    J Hypertens; 2008 Jun; 26(6):1209-15. PubMed ID: 18475159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase.
    Yuen CY; Wong WT; Tian XY; Wong SL; Lau CW; Yu J; Tomlinson B; Yao X; Huang Y
    Cardiovasc Res; 2011 Apr; 90(1):122-9. PubMed ID: 21156825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation.
    Tsukuda K; Mogi M; Iwanami J; Min LJ; Sakata A; Jing F; Iwai M; Horiuchi M
    Hypertension; 2009 Oct; 54(4):782-7. PubMed ID: 19635982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telmisartan prevents angiotensin II-induced endothelial dysfunction in rabbit aorta via activating HGF/Met system and PPARγ pathway.
    Hu ZP; Fang XL; Qian HY; Fang N; Wang BN; Wang Y
    Fundam Clin Pharmacol; 2014 Oct; 28(5):501-11. PubMed ID: 24188213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telmisartan, a dual ARB/partial PPAR-γ agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetes.
    Goyal SN; Bharti S; Bhatia J; Nag TC; Ray R; Arya DS
    Diabetes Obes Metab; 2011 Jun; 13(6):533-41. PubMed ID: 21320264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telmisartan inhibits cytokine-induced nuclear factor-kappaB activation independently of the peroxisome proliferator-activated receptor-gamma.
    Nakano A; Hattori Y; Aoki C; Jojima T; Kasai K
    Hypertens Res; 2009 Sep; 32(9):765-9. PubMed ID: 19590508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitroglycerin-induced endothelial dysfunction and tolerance involve adverse phosphorylation and S-Glutathionylation of endothelial nitric oxide synthase: beneficial effects of therapy with the AT1 receptor blocker telmisartan.
    Knorr M; Hausding M; Kröller-Schuhmacher S; Steven S; Oelze M; Heeren T; Scholz A; Gori T; Wenzel P; Schulz E; Daiber A; Münzel T
    Arterioscler Thromb Vasc Biol; 2011 Oct; 31(10):2223-31. PubMed ID: 21757654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-gamma activation.
    Younis F; Stern N; Limor R; Oron Y; Zangen S; Rosenthal T
    Metabolism; 2010 Aug; 59(8):1200-9. PubMed ID: 20070992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telmisartan reduces atrial arrhythmia susceptibility through the regulation of RAS-ERK and PI3K-Akt-eNOS pathways in spontaneously hypertensive rats.
    Wang WW; Zhang FL; Chen JH; Chen XH; Fu FY; Tang MR; Chen LL
    Can J Physiol Pharmacol; 2015 Aug; 93(8):657-65. PubMed ID: 26158699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telmisartan protects against cognitive decline via up-regulation of brain-derived neurotrophic factor/tropomyosin-related kinase B in hippocampus of hypertensive rats.
    Kishi T; Hirooka Y; Sunagawa K
    J Cardiol; 2012 Dec; 60(6):489-94. PubMed ID: 22948091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.